420 related articles for article (PubMed ID: 21427581)
1. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Behrens F; Koehm M; Burkhardt H
Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Singer O; Gibofsky A
Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
4. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Ann Rheum Dis; 2012 Mar; 71(3):374-7. PubMed ID: 21972242
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Silverman E; Mouy R; Spiegel L; Jung LK; Saurenmann RK; Lahdenne P; Horneff G; Calvo I; Szer IS; Simpson K; Stewart JA; Strand V;
N Engl J Med; 2005 Apr; 352(16):1655-66. PubMed ID: 15843668
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
11. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
Murdaca G; Spanò F; Puppo F
Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
[TBL] [Abstract][Full Text] [Related]
12. [Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].
Burmester GR
MMW Fortschr Med; 2004 Sep; 146(37):10. PubMed ID: 15887693
[No Abstract] [Full Text] [Related]
13. Leflunomide.
Cannon GW; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):295-309, vi. PubMed ID: 15172042
[TBL] [Abstract][Full Text] [Related]
14. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
Kitahara K; Kawai S
Curr Opin Rheumatol; 2007 May; 19(3):238-45. PubMed ID: 17414949
[TBL] [Abstract][Full Text] [Related]
16. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
17. An update on methotrexate.
Braun J; Rau R
Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
[TBL] [Abstract][Full Text] [Related]
18. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Schnabel A; Gross WL
Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
[No Abstract] [Full Text] [Related]
19. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
Smolen JS; Emery P; Kalden JR; Van Riel PL; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():13-20. PubMed ID: 15170903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
